Osteoporosis Treatment Market Scope And Analysis

Report Code : TIPRE00004071
Category : Life Sciences

No. of Pages : 150

Buy Now

Osteoporosis Treatment Market Analysis and Scope (2024 to 2031)

Buy Now

Osteoporosis Treatment Market Report Scope

Report Attribute	Details
Market size in 2023	US$ 16.83 Billion
Market Size by 2031	US$ 22.72 Billion
Global CAGR (2023 - 2031)	3.8%
Historical Data	2021-2022
Forecast period	2024-2031
Segments Covered	By Drug Class Calcitonin Bisphosphonates Selective Estrogen Receptor Modulators PTH-Related Anabolic By Type Primary Osteoporosis Secondary Osteoporosis By Route of Administration Oral Injectable By Distribution Channel Hospital Pharmacies Retail Pharmacies Online Pharmacies
Regions and Countries Covered	North America US Canada Mexico Europe UK Germany France Russia Italy Rest of Europe Asia-Pacific China India Japan Australia Rest of Asia-Pacific South and Central America Brazil Argentina Rest of South and Central America Middle East and Africa South Africa Saudi Arabia UAE Rest of Middle East and Africa
Market leaders and key company profiles	Pfizer Inc Amgen Inc Cadila Pharmaceuticals Eli Lilly and Company Daiichi Sankyo Company Limited Teva Pharmaceuticals Inc Asahi Kasei Corporation Novartis AG Chugai Pharmaceutical Co Ltd Teijin Pharma Limited

Key Player Analysis:

Pfizer Inc.; Amgen Inc.; Cadila Pharmaceuticals; Eli Lilly and Company; Daiichi Sankyo Company, Limited; Teva Pharmaceuticals Inc.; Asahi Kasei Corporation; Novartis AG; Chugai Pharmaceutical Co., Ltd.; and Teijin Pharma Limited are among the key players profiled in the osteoporosis treatment market report.

Recent Developments:

Companies operating in the osteoporosis treatment market adopt mergers and acquisitions as key growth strategies. As per company press releases, a few recent market developments are listed below:

In October 2021, Entera Bio, a leading biotechnology company, released key data for its mid-stage oral osteoporosis drug formulation study. The company has advanced Phase 3 registration of this study.
In August 2021, the Drug Controller General of India (DCGI) gave Marketing Authorization (MA) to Enzene Biosciences Ltd, for its biosimilar drug Denosumab, which is indicated for treating osteoporosis in adults.
In January 2021, Theramex, a pharmaceutical company headquartered in London, launched the osteoporosis drug Livogiva in Europe.